Breaking News, Collaborations & Alliances

TFF Pharmaceuticals Signs Worldwide Licensing Agreement with Union Therapeutics

Will develop dry powder forms of niclosamide as a potential COVID-19 treatment.

By: Contract Pharma

Contract Pharma Staff

TFF Pharmaceuticals Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, has entered into a worldwide exclusive licensing agreement with Union Therapeutics A/S for its TFF technology used in combination with niclosamide.   Under the terms of the agreement, Union will acquire an option to obtain a worldwide exclusive license of TFF Pharmaceuticals to its TFF technolog...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters